

August 4, 2022
 Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President and Chief Executive Officer
 (Securities Code: 4582)

Revision to Earnings Forecast for FY 2022

TOKYO, Japan, August 4, 2022 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio" or the "Company") today announced that the Company's Board of Directors today approved the following revision to the Earnings Forecast for fiscal year ending December 31, 2022. The Earnings Forecast was previously announced on February 10, 2022. The revision reflects the Company's current performance trends and outlook.

1. Revision to Earnings Forecast for FY 2022 (January 1, 2022 to December 31, 2022)

	Net Sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Forecast (A)	10,992	1,770	1,750	1,480	38.63
Actual (B)	10,003	1,770	1,750	1,480	38.35
Difference (B-A)	(989)	—	—	—	—
Percentage Change (%)	(9.0)	—	—	—	—
[Reference] Prior Year Results (FY 2021)	—	—	—	—	—

*The Company's results for the previous fiscal year were on a non-consolidated basis.

	Net Sales	Operating Profit	Ordinary Profit	Net Profit	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
[Reference] Prior Year Results (FY 2021)	8,256	1,016	1,001	2,032	53.04

2. Reasons for changes

The Company reduced its initial projection for sales by 989 million yen to 10,003 million yen in light of delays in treatments and constraints in sales activities caused by continuing restrictions on visits to medical institutions due to the spread of COVID-19 and the NHI price listing of a generic drug in June

2022. The Company maintains its initial forecast for all profit categories, which are operating profit of 1,770 million yen, ordinary profit of 1,750 million yen, and profit attributable to owners of the parent of 1,480 million yen. The profit targets are unchanged as the Company anticipates the impact of lower sales to be offset by reduced SG&A expense while maintaining the highest priority on R&D investment in the Company's global development plan for antiviral drug brincidofovir.

*Earnings forecasts, financial projections, and other forecasts or forward looking statements contained in this disclosure have been prepared by the Company at its discretion and based on information available to the Company as of the date of this disclosure. Actual results may vary materially from the information contained in this disclosure as a result of changes to business, economic, financial, or other assumptions and conditions.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125